<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116634</url>
  </required_header>
  <id_info>
    <org_study_id>rokhsareh</org_study_id>
    <secondary_id>stem cell injection in ALS</secondary_id>
    <nct_id>NCT02116634</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alzahra Hospital, Iran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alzahra Hospital, Iran</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whether the mesenchymal injection on ALS patients is effective or not?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After and before transplantation, all of the patients will visit by experience neurologist
      and evaluate with EMG (electromyography) and spirometry procedure and clinical progression
      of disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effect of Intrathecal injection of autologous mesenchymal stem cells in improving the symptoms of ALS</measure>
    <time_frame>every 6 months up  2 years after transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALS-FRS(functional rating scale) score and EMG scale</measure>
    <time_frame>before transplatation and at 6 months, 12months, 18 months and 24 months after transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (forced vital capacity)and DWSE±QoL score</measure>
    <time_frame>before transplantation and every 6 months up 2 years after transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cell</intervention_name>
    <description>intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline</description>
    <arm_group_label>mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. sporadic ALS according to escorial criteria

          2. onset of disease with spinal cord involvement, Less than 3 years of disease onset
             with disease progression at 6 past months

          3. mild to moderate spinal and bulbar disability,at least having score3 in swallowing, 2
             in chewing and waking in ALS-FRS and FVC(functional vital capacity) equal or more
             than 50% of prediction amount

          4. normal polysomnography

          5. Signed consent form

        Exclusion Criteria:

          1. pregnancy or lactation,

          2. vascular disease,diabetes, systemic disease as cancer, autoimmune , liver or
             hematologic disease

          3. Hospitalization due to serious illness in the last two months

          4. survival time less than two years

          5. Hypersensitivity to any component used in the cell culture
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>keivan basiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan neurosciences research center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurosciences Research Center</name>
      <address>
        <city>Isfahan</city>
        <zip>0098311</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>rokhsareh meamar, MD,Ph.D</last_name>
      <phone>00989133091206</phone>
      <email>meamar@pharm.mui.ac.ir</email>
    </contact>
    <contact_backup>
      <last_name>keivan basiri, MD</last_name>
      <phone>00989133290713</phone>
      <email>basiri@med.mui.ac.ir</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alzahra Hospital, Iran</investigator_affiliation>
    <investigator_full_name>rokhsareh meamar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
